此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

在患有慢性肾脏疾病阶段的患者中,使用支持AI-AI-AI-ECG设备的高钾血症监测3-5 (POCKET)

2026年11月10日 更新者:Peking University First Hospital

在患有慢性肾脏疾病阶段的患者中,使用支持AI-AI-AI-ECG设备的高钾血症监测3-5的患者,以降低高钾血症的发生率

The clinical trial will be conducted in a real-world outpatients setting with the goal of learning if monitoring serum potassium frequently among patients with moderate-to-advanced stages of chronic kidney disease leading to optimal management of hyperkalemia (the reduced occurrence of serum potassium ≥ 5.0 mmol/L during 6 months of follow-up). It will also learn about the adherence of using a mobile monitoring device.

Participants will:

  • Measure their serum potassium using an AI-enhanced point-of-care ECG device at least twice per week
  • Receive health education prompts to reduce intake of potassium rich foods if their electrocardiogram device measured serum potassium is abnormal
  • Receive alerts to visit nephrology clinic if their electrocardiogram device measured serum potassium is continuously abnormal

研究概览

研究类型

介入性

注册 (估计的)

1066

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100034
        • 招聘中
        • Peking University First Hospital
        • 接触:
    • Guangxi
      • Nanning、Guangxi、中国、530021
        • 尚未招聘
        • The First Affiliated Hospital of Guangxi Medical University
        • 接触:
    • Hubei
      • Wuhan、Hubei、中国、430063
        • 尚未招聘
        • Hubei Provincial Hospital of TCM
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 99年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients with chronic kidney disease stages 3b-5 (eGFR: 10 - <45 ml/min/1.73m²)
  • Patients with regular visits in the study sites to manage their chronic kidney disease (≥ 1 visit per 3 months during the past year before enrollment)
  • Willingness to participate in the study with signed informed consent

Exclusion Criteria:

  • Patients already under kidney replacement therapy or will receive kidney replacement therapy in 6 months
  • Unwillingness or without the ability to monitor hyperkalemia using the study device
  • Patients with heart pacemaker implanted

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Monitoring plasma potassium using ECG device

Patients in this arm will use AI-enhanced point-of-care ECG device to monitor their serum potassium level every 3 days for 6 months in addition to their regular outpatients follow-up. If ECG device detected hyperkalemia was reported, more intensive monitoring, education on diet or offer of making outpatient appointment, as appropriate, will be provided.

A mobile AI-enhanced electrocardiogram device will be used to help patients monitor hyperkalemia. The device, shaped like a stick of chewing gum, collects time-series data of electrocardiogram lead I through two electrodes. Deep convolutional neural network algorithm can read the data and generated categories of plasma potassium (<5 mmol/L, 5 - <5.5 mmol/L, 5.5 - <6.0 mmol/L and ≥ 6.0 mmol/L). Study participants receive the device after randomization. The staff establishes a WeChat group for each participant and reminds them to monitor plasma potassium every 3 days. When the detected plasma potassium category falls in 5 - <5.5 mmol/L, they will be reminded to watch diet and to verify plasma potassium again. More intensive reminding (once daily) will be sent if plasma potassium category falls in 5.5 - <6.0 mmol/L or ≥ 6.0 mmol/L. An extra outpatient appointment will also be made as soon as possible for the patients when their detected plasma potassium category is ≥ 6.0 mmol/L.

无干预:Regular outpatients follow-up

Patients in this arm will just follow their regular outpatients care without additional intervention.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of serum potassium ≥ 5.0 mmol/L
大体时间:Six months (+1 month if outpatients visit delayed) after enrollment into the study

The serum potassium should be the laboratory measured one, which is obtained in the 3(±1) month and 6(±1) month follow-up in outpatients visit.

Six months (+1 month if outpatients visit delayed) after enrollment into the study

次要结果测量

结果测量
措施说明
大体时间
Average level of serum potassium
大体时间:Six month (+1 month if outpatients visit delayed) after enrollment into the study

The serum potassium should be the laboratory measured one, which is obtained in the 3(±1) month and 6(±1) month follow-up in outpatients visit.

Six month (+1 month if outpatients visit delayed) after enrollment into the study
Frequency of using AI-enhanced ECG device to monitor serum potassium
大体时间:Six months (+1 month if outpatients visit delayed) after enrollment into the study and 3 months (+1 month if outpatients visit delayed) after the 6 months of intervention.

The frequency will be monitored in intervention period for the intervention group and after intervention (up to 4 months) for both the original intervention and control groups.

Six months (+1 month if outpatients visit delayed) after enrollment into the study and 3 months (+1 month if outpatients visit delayed) after the 6 months of intervention.

其他结果措施

结果测量
措施说明
大体时间
Incidence of serum potassium ≥ 5.0 mmol/L after the intervention period
大体时间:Three months (+1 month if outpatients visit delayed) after the 6 months of intervention

We collect incidence of serum potassium ≥ 5.0 mmol/L after the intervention period to see whether there is still a gap between the original intervention and control groups with the latter one having obtained the device.

Three months (+1 month if outpatients visit delayed) after the 6 months of intervention

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年4月2日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2028年5月31日

研究注册日期

首次提交

2025年3月24日

首先提交符合 QC 标准的

2025年3月24日

首次发布 (实际的)

2025年3月30日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

IPD used in the results publication will be shared upon reasonable request.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅